ALS in Medical Technology

Neuralstem's ALS Trial on Clinical Hold

ROCKVILLE, Md., Feb. 20 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today its spinal cord stem cell trial to treat ALS is on clinical hold and that the Federal Drug Administration (FDA) has provided the Company with specific comments, questions and recommendations...

Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program

PITTSBURGH, Sept. 24 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") today announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070...

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

Make Synaptic Contact with Host Motor Neurons ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Transplanted human neural stem cells (hNSCs) developed by Neuralstem, Inc. (NYSE Alternext US: CUR) made synaptic contacts with the motor neurons of rats with ALS-like symptoms, a paper published i...

Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS

PITTSBURGH, Oct. 15 /PRNewswire/ -- Knopp Neurosciences Inc. ("Knopp") announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation to KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS). (Logo: http://www.ne...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

Trophos Describes Identification, Characterization and Broad Neuroprotective Properties of TRO19622 in Journal of Pharmacology and Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a Novel Drug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, Ju...

CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising mul...

CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with ar...

AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis

...han Status for the treatment of Amyotrophic Lateral Sclerosis (ALS). als is the most common form of Motor Neuron Disease (MND), also known as Lou Ge...cebo controlled, Randomised Clinical Trial to determine whether later stage als patients with poor respiratory function can be seen to benefit from the med...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

...health at 180 days post treatment. -- Initiation of repeat dosing Phase 2 clinical trials of SB-509 in stem cell mobilization (SB-509-703) and als (SB-509-801). -- Completion of enrollment and expansion of Phase 2 clinical trial in subjects with moderate to severe DN (SB-509-701). Present...

Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology

...ational New Drug) application with the FDA for the als trial in the next few weeks, and hopes to start th...ompany's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRA...stigational New Drug) application with the FDA for als in the fall. Cautionary Statement Regarding Forw...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

...without assistance. Fifty percent of patients with als die within three to five years of diagnosis. Curre...modest clinical benefit, extending the survival of als patients by approximately three months. "Initiat...cts with a motor neuron and muscle disease such as als is an obvious next step in the evaluation of this ...

ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease

...MBRIDGE, Mass., Aug. 19 /PRNewswire-USNewswire/ -- als Therapy Development Institute (ALS TDI) announced ...y effective therapeutics. To facilitate additional als patient participation, ALS TDI has recently execut...d Steve Perrin, Ph.D., chief scientific officer of als TDI. ...

Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications

...ator Clinical Trials Also Underway For als Patients CLEVELAND, June 18 /PRNewswire/ -- Syna...ttp://www.synapsebiomedical.com/news/success/ . als Clinical Trials Also Underway Amyotrophic Latera...r. It is estimated that fewer than five percent of als patients choose to be placed on ventilators. The...

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

... Follow-on Biologics in Clinical Studies by Year-End - Enrollment On Track in MMD Clinical Study - als Expanded Access Program Continues to Enroll - Insmed Generates $2.3 million in Cost Recovery Revenue Through Expanded Access Program ...

Neuralstem Announces Issuance of Core Technology Patent in Europe

...rograms currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with als (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysi...

ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science

...lateral sclerosis -- ALS, or Lou Gehrig's disease. als is a progressive and fatal neurodegenerative disea...cally. "The ongoing data mining efforts at the als TDI are identifying hundreds of therapeutic target... Steven Perrin, Ph.D., Chief Scientific Officer of als TDI. "The publication of the Allen Brain Atlas--Mo...

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

...3) to evaluate the effect of SB-509 on stem cell mobilization -- Initiate a Phase 2 clinical trial to evaluate SB-509 for the treatment of als (Amyotrophic Lateral Sclerosis, also known as "Lou Gehrig's disease"). -- Advance ZFP Therapeutic pipeline by initiating Phase 1 clinical trial...

Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development

...at Trophos are developing unique compounds that improve mitochondrial function and that are currently being evaluated in patients for the treatment of als and diabetic neuropathy. Dr. Pruss will test whether these compounds are neuroprotective in an animal model of Parkinson's disease. Grant abstract...

Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis

...the full-year 2007. The study utilizes a Revised als Functional Rating Scale (ALSFRS) to monitor the pr...e progressive degeneration of the motor neurons in als eventually leads to their death. When the motor ne...e of the disease may become totally paralyzed. The als Association believes that 5,600 people in the U.S....

Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy

...ntly being studied as a treatment for several serious medical conditions, including two neuromuscular disorders, Myotonic Muscular Dystrophy (MMD) and als (Lou Gehrig's Disease); HIV-Associated Adipose Redistribution Syndrome (HARS); and retinopathy of prematurity (ROP). About Insmed Insmed Inc. is a...

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

...n) which recently completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130 and CERE-140 are in preclinical development for als (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001 and is a former subsidiary of Cell Genesys, Inc. (Nas...

Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

...sequential pools of 60. Our ability to halt the trial early underscores the potential efficacy of AL-08, which can be further evaluated in a Phase III als clinical trial." "We are pleased that AL-08/celecoxib slowed deterioration in ALS- Functional Score compared to the other treatment and believe that...

Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND

.... The three trials were conducted by the Northeast als Consortium (NEALS), Carolinas Medical Center and U...oint of median survival and secondary endpoints of als functional scores. "These data points support AL-02's positive effect on the survival rate of als patients," stated Belinda Tsao-Nivaggioli, Chairma...

KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model

...to alter microtubule dynamics in nerve cells in preclinical studies (J Biol Chem. 2007 Jun 13). KineMed researchers have discovered that patients with als have more rapid rates of turnover of microtubules, which are integral to the structure and functionality of the motor neurons affected by the disease....

ALS TDI Completes Gene Expression Profile of Lou Gehrig's Disease in Mice

...ase CAMBRIDGE, Mass., Oct. 2 /PRNewswire/ -- The als Therapy Development Institute (ALS TDI) today anno...se of a comprehensive gene-expression database for als with the profiling of the SOD1 mouse model of amyo...t is the foundation that will enable scientists at als TDI to understand the biological mechanisms associ...

CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies

...ter a Phase IIb clinical trial with arimoclomol in als in the second half of 2007, subject to U.S. Food a...an Drug status to arimoclomol for the treatment of als and has also been granted orphan medicinal product status for the treatment of als by the European Commission. For more information, ...

CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal

...ter a Phase IIb clinical trial with arimoclomol in als in the second half of 2007, subject to U.S. Food a...an Drug status to arimoclomol for the treatment of als and has also been granted orphan medicinal product status for the treatment of als by the European Commission. The Company is also de...

Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study

...ical needs, including HIV-associated adipose redistribution syndrome, retinopathy of prematurity and amyotrophic lateral sclerosis (otherwise known as als or Lou Gehrig's disease). About Insmed Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the tre...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

... Loss of muscle mass and strength is a serious clinical consequence of several types of diseases and conditions: (1) neuromuscular diseases, such as als and muscular dystrophy, in which patients suffer from the loss of muscle strength and function which ultimately leads to respiratory failure and death...

Accelreon Pharma's ACE-031Shown to Increase Muscle Mass in Preclinical Studies

...s Loss of muscle mass and strength is a serious clinical consequence of several types of diseases and conditions: (1) neuromuscular diseases, such as als and muscular dystrophy, in which patients suffer from the loss of muscle strength and function which ultimately leads to respiratory failure and death...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

...eral sclerosis patients and the second observed the effect of umbilical cord blood mesenchymal stem cell transplantation on nervous system function of als patients. About Shenzhen Biotech Co., Ltd. Beike is a leading biotechnology company founded with capital from Beijing University, Hong Kong Univer...